alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 23

                  CONSENT OF INDEPENDENT CHARTERED ACCOUNTANTS

      We  consent  to the use in  this  Annual  Report  on  Form  10-K of  Mitel
Corporation of our report with respect to the Company's  consolidated  financial
statements for the year ended March 30, 2001.

      We  consent  to  the   incorporation  by  reference  in  the  Registration
Statements  (Forms S-8 numbers  2-74833,  2-78545,  2-84711,  2-86511,  2-92200,
2-92201, 2-92494, 33-1371, 33-9682, 33-45716, 33-98946 and 333-66315) pertaining
to the Stock  Purchase Plan for Eligible U.S.  Employees,  the Stock Option Plan
for Key  Employees,  the Basic Stock Option Plan,  The Stock Option Plan for Key
Employees,  the 1984 Stock Option Plan,  the Basic Stock Option Plan, the United
Kingdom  Savings  Related  Share  Option  Scheme,  the 1985  Stock  Option/Stock
Purchase Plan, the Preferred Share Purchase Plan, the 1991 Stock Option Plan for
Key Employees and Stock Option Grant to Anthony F.  Griffiths and the 1991 Stock
Option Plan for Key Employees and Non-Employee  Directors  respectively,  and in
the  Registration  Statements  (Forms S-3  numbers  2-81989,  2-82262,  2-88432,
2-91496 and 2-96412) of Mitel Corporation,  and in the related prospectuses,  of
our report dated May 4, 2001,  except as to note 27 which is as of June 7, 2001,
with  respect to the  consolidated  financial  statements  of Mitel  Corporation
incorporated  by reference  in the Annual  Report (Form 10-K) for the year ended
March 30, 2001.

      Our  audit  also  included  the  financial  statement  schedule  of  Mitel
Corporation  listed in Item 14(a)2.  This schedule is the  responsibility of the
Company's  management.  Our responsibility is to express an opinion based on our
audit. In our opinion,  the financial statement schedule referred to above, when
considered  in  relation  to the basic  financial  statements  taken as a whole,
presents fairly in all material respects the information set forth therein.

      Ottawa, Canada,
                                                        /s/ ERNST & YOUNG LLP
                                                       ------------------------
      June 28, 2001.                                        ERNST & YOUNG LLP
NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

LEWIS A. HARRY, Jr.,

 Plaintiff - Appellant,

 v.

ANNA M. JACOBS; et al.,

 Defendants - Appellees.

No. 14-16726

D.C. No. 4:10-cv-00736-CKJ

MEMORANDUM*

Appeal from the United States District Court

for the District of Arizona

Cindy K. Jorgenson, District Judge, Presiding

Submitted April 13, 2016** 

Before: FARRIS, TALLMAN, and BYBEE, Circuit Judges. 

Arizona state prisoner Lewis A. Harry, Jr., appeals pro se from the district

court’s summary judgment in his 42 U.S.C. § 1983 action alleging that defendant

Talley violated his First Amendment rights. We have jurisdiction under 28 U.S.C.

§ 1291. We review de novo summary judgment on the basis of qualified

FILED

APR 19 2016

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS

 * This disposition is not appropriate for publication and is not precedent

except as provided by 9th Cir. R. 36-3.

 ** The panel unanimously concludes this case is suitable for decision

without oral argument. See Fed. R. App. P. 34(a)(2).
immunity. McSherry v. City of Long Beach, 584 F.3d 1129, 1134 (9th Cir. 2009). 

We affirm. 

The district court properly granted summary judgment for Talley on the

basis of qualified immunity because it would not have been clear to every

reasonable official that it was unlawful under the circumstances to temporarily take

possession of religious property to allow for approval by the chaplain and to not

ensure the property was returned earlier. See Ashcroft v. al-Kidd, 131 S. Ct. 2074,

2080, 2083 (2011) (discussing qualified immunity and noting that a right is clearly

established only if “every reasonable official would have understood that what he

is doing violates that right” (citation and internal quotation marks omitted)); see

also Walker v. Beard, 789 F.3d 1125, 1138 (9th Cir. 2015) (elements of a free

exercise claim).

The district court did not abuse its discretion in granting Talley’s request to

file a second motion for summary judgment to further develop the record. See

Hoffman v. Tonnemacher, 593 F.3d 908, 911-12 (9th Cir. 2010) (setting forth

standard of review and explaining that “allowing a party to file a second motion for

summary judgment is logical, and it fosters the just, speedy, and inexpensive

resolution of suits” (citation and internal quotation marks omitted)).

We do not consider the merits of Harry’s remaining claims because Harry

2 14-16726
does not challenge the basis for their dismissal.

AFFIRMED.

3 14-16726
§ 582.1137 Ammonium carbonate. ( a ) *Product.* Ammonium carbonate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
I 

118TH CONGRESS 

2D SESSION H. R. 7304 

To amend title II of the Social Security Act to establish that benefits paid 

to a parent caring for the child of an individual who died while performing active duty as a member of the Armed Services are not subject 

to deductions under the retirement earnings test. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 7, 2024 

Mr. WALTZ (for himself, Ms. HOULAHAN, Mr. BISHOP of Georgia, Mr. 

BACON, Mr. DAVIS of North Carolina, and Mr. NUNN of Iowa) introduced the following bill; which was referred to the Committee on Ways 

and Means 

A BILL 

To amend title II of the Social Security Act to establish 

that benefits paid to a parent caring for the child of 

an individual who died while performing active duty as 

a member of the Armed Services are not subject to 

deductions under the retirement earnings test. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Protecting the Fami5 lies of Our Fallen Patriots Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7304 IH

1 SEC. 2. EXEMPTION FROM RETIREMENT EARNINGS TEST. 

2 (a) IN GENERAL.—Section 203(b) of the Social Secu3 rity Act (42 U.S.C. 403(b)) is amended by adding at the 

4 end the following: 

5 ‘‘(3) In any case in which an surviving spouse or sur6 viving divorced parent is entitled to a mother’s or father’s 

7 insurance benefit under section 202(g) and such benefit 

8 is based on the wages and self-employment income of a 

9 deceased individual who died while performing active duty 

10 as a member of the Armed Forces, the benefit to which 

11 such surviving spouse or surviving divorced parent is enti12 tled on the basis of the wages and self-employment income 

13 of such deceased individual shall not be subject to deduc14 tions under this subsection.’’. 

15 (b) EFFECTIVE DATE.—The amendments made by 

16 this section shall apply with respect to benefits payable 

17 for months that begin on or after the date of enactment 

18 of this Act. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
§ 211.80 General requirements. ( a ) There shall be written procedures describing in sufficient detail the receipt, identification, storage, handling, sampling, testing, and approval or rejection of components and drug product containers and closures; such written procedures shall be followed.
( b ) Components and drug product containers and closures shall at all times be handled and stored in a manner to prevent contamination.
( c ) Bagged or boxed components of drug product containers, or closures shall be stored off the floor and suitably spaced to permit cleaning and inspection.
( d ) Each container or grouping of containers for components or drug product containers, or closures shall be identified with a distinctive code for each lot in each shipment received. This code shall be used in recording the disposition of each lot. Each lot shall be appropriately identified as to its status (i.e., quarantined, approved, or rejected).
<TABLE> <S> <C>

<ARTICLE> 5
<RESTATED> 
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               MAR-01-1998
<CASH>                                           5,897
<SECURITIES>                                         0
<RECEIVABLES>                                   18,251
<ALLOWANCES>                                       673
<INVENTORY>                                          0
<CURRENT-ASSETS>                                24,986
<PP&E>                                           7,875
<DEPRECIATION>                                   2,671
<TOTAL-ASSETS>                                  32,738
<CURRENT-LIABILITIES>                           13,377
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        20,618
<OTHER-SE>                                     (2,300)
<TOTAL-LIABILITY-AND-EQUITY>                    32,738
<SALES>                                         21,230
<TOTAL-REVENUES>                                21,230
<CGS>                                                0
<TOTAL-COSTS>                                   11,847
<OTHER-EXPENSES>                                 7,856
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  99
<INCOME-PRETAX>                                  1,498
<INCOME-TAX>                                       625
<INCOME-CONTINUING>                                873
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       873
<EPS-PRIMARY>                                     0.07
<EPS-DILUTED>                                     0.07
        

</TABLE>
§ 582.3862 Sulfur dioxide. ( a ) *Product.* Sulfur dioxide.
( b ) [Reserved]
( c ) *Limitations, restrictions, or explanation.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice, except that it is not used in meats or in food recognized as source of vitamin B1.
Exhibit 23.1

Consent of Stegman & Company

GRAPHIC

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board
of Directors and Stockholders
First Mariner Bancorp
Baltimore, Maryland

We
consent to the incorporation by reference in the Registration Statements (Nos. 333-60961, 333-60963, 333-60967, 333-107669,
333-114073 and 333-122464) on Form S-8 and (No. 333-107670) on Form S-3 of First Mariner Bancorp of our report dated
March 23, 2010, relating to the 2009 consolidated financial statements included in the annual report on Form 10-K of First Mariner Bancorp, for the year ended
December 31, 2009.



Baltimore,
Maryland
March 24, 2010

---



QuickLinks
# C_2014388EN.01003001.xml

| 3.11.2014 | EN | Official Journal of the European Union | C 388/30 |
| --- | --- | --- | --- |

3.11.2014

EN

Official Journal of the European Union

C 388/30

---

Action brought on 25 July 2014 — ZZ v Commission

(Case F-74/14)

2014/C 388/37

Language of the case: French

Parties

Parties

Applicant: ZZ (represented by: S. Orlandi, lawyer)

Applicant:

Defendant: European Commission

Defendant:

Subject-matter and description of the proceedings

Subject-matter and description of the proceedings

Declaration of the unlawfulness of Article 7 of Annex V and Article 8 of Annex VII to the new Staff Regulations of Officials and of the annulment of the decision withdrawing from the applicant the benefit of travelling time and reimbursement of travel costs between her place of employment and her place of origin to which she was entitled before the entry into force of that new provision of the Staff Regulations.

Form of order sought

Form of order sought

| — | Declare Articles 7 of Annex V to the Staff Regulations and 8 of Annex VII to the Staff Regulations unlawful; |
| --- | --- |

—

Declare Articles 7 of Annex V to the Staff Regulations and 8 of Annex VII to the Staff Regulations unlawful;

| — | Annul the decision no longer to grant the applicant any travelling time or the reimbursement of annual travel costs with effect from 2014; |
| --- | --- |

—

Annul the decision no longer to grant the applicant any travelling time or the reimbursement of annual travel costs with effect from 2014;

| — | Order the Commission to pay the costs. |
| --- | --- |

—

Order the Commission to pay the costs.

---
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 12-1490

CYNTHIA GAYLE SMITH,

Plaintiff - Appellant,

v.

TIMOTHY PURNELL,

Defendant - Appellee.

Appeal from the United States District Court for the Eastern 

District of Virginia, at Alexandria. James C. Cacheris, Senior

District Judge. (1:11-cv-00922-JCC-IDD)

Submitted: August 16, 2012 Decided: August 20, 2012

Before KING and THACKER, Circuit Judges, and HAMILTON, Senior 

Circuit Judge.

Affirmed by unpublished per curiam opinion.

Cynthia Gayle Smith, Appellant Pro Se. Mikhael David Charnoff, 

Danny Mark Howell, Courtney South Schorr, SANDS ANDERSON, PC, 

McLean, Virginia, for Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Cynthia Gayle Smith appeals the district court’s 

orders denying her motion to amend her civil complaint, 

dismissing the complaint, and denying reconsideration. We have 

reviewed the record and find no reversible error. Accordingly, 

we affirm for the reasons stated by the district court. Smith 

v. Purnell, No. 1:11-cv-00922-JCC-IDD (E.D. Va. Dec. 9, 2011 & 

Mar. 20, 2012). We dispense with oral argument because the 

facts and legal contentions are adequately presented in the 

materials before the court and argument would not aid the 

decisional process.

AFFIRMED
Exhibit 99.2

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In  connection  with  the  Quarterly  Report  of  Anaren  Microwave,  Inc.  (the
"Company") on Form 10-Q for the quarter  ended  September 30, 2002 as filed with
the Securities  and Exchange  Commission on the date hereof (the  "Report"),  I,
Joseph E.  Porcello,  Vice  President,  Finance and  Treasurer  of the  Company,
certify,  pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)   the Report fully complies with the  requirements of Section 13(a) or 15(d)
      of the Securities Exchange Act of 1934; and

(2)   the information  contained in the Report fairly presents,  in all material
      respects,  the  financial  condition  and  results  of  operations  of the
      Company.

/s/ Joseph E. Porcello
-------------------------------------
Joseph E. Porcello
Vice President, Finance and Treasurer
October 23, 2002
§ 526.1698 Penicillin G procaine and novobiocin. ( a ) *Specifications.* Each single-use, 10-milliliter syringe contains a suspension of: ( 1 ) Penicillin G procaine equivalent to 100,000 units penicillin G and 150 milligrams (mg) novobiocin as novobiocin sodium; or
( 2 ) Penicillin G procaine equivalent to 200,000 units penicillin G and 400 mg novobiocin as novobiocin sodium.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See §§ 556.460 and 556.510 of this chapter.
( d ) *Conditions of use for syringe described in paragraph (a)(1) of this section in lactating cows* — ( 1 ) *Amount.* Infuse the contents of one syringe (equivalent to 100,000 units penicillin G and 150 mg novobiocin) into each infected quarter after milking. Repeat once after 24 hours.
( 2 ) *Indications for use.* For the treatment of mastitis caused by susceptible strains of *Staphylococcus aureus, Streptococcus agalactiae, Streptococcus dysgalactiae,* and *Streptococcus uberis* in lactating cows.
( 3 ) *Limitations.* For udder instillation in lactating cows only. Do not milk for at least 6 hours after treatment; thereafter, milk at regular intervals. Milk taken from treated animals within 72 hours (6 milkings) after the latest treatment must not be used for food. Treated animals must not be slaughtered for food for 15 days following the latest treatment. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( e ) *Conditions of use for syringe described in paragraph (a)(2) of this section in lactating cows* — ( 1 ) *Amount.* Infuse the contents of one syringe (equivalent to 200,000 units penicillin G and 400 mg novobiocin) into each quarter at dry off.
( 2 ) *Indications for use.* For the treatment of subclinical mastitis caused by susceptible strains of *Staphylococcus aureus* and *Streptococcus agalactiae* in dry cows.
( 3 ) *Limitations.* For udder instillation in dry cows only. Do not use less than 30 days prior to calving. Milk from treated cows must not be used for food during the first 72 hours after calving. Treated animals must not be slaughtered for food for 30 days following udder infusion. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37336, Aug. 18, 1992; 57 FR 42623, Sept. 15, 1992; 79 FR 10973, Feb. 27, 2014; 84 FR 32993, July 11, 2019. Redesignated and amended at 86 FR 13187, Mar. 8, 2021; 88 FR 14901, Mar. 10, 2023]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1050 Alkaline phosphatase or isoenzymes test system. ( a ) *Identification.* An alkaline phosphatase or isoenzymes test system is a device intended to measure alkaline phosphatase or its isoenzymes (a group of enzymes with similar biological activity) in serum or plasma. Measurements of alkaline phosphatase or its isoenzymes are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases.
( b ) *Classification.* Class II.
<PAGE>   1


                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K
                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934



Date of Report (Date of earliest event reported) May 12, 1999

                              THE LOEWEN GROUP INC.
             (Exact name of registrant as specified in its charter)



    British Columbia, Canada             0-18429                 98-0121376
-------------------------------    ----------------------    -------------------
(State or other jurisdiction of   (Commission File Number)     (IRS Employer
         incorporation)                                      Identification No.)




4126 Norland Avenue, Burnaby, British Columbia               V5G 3S8       
----------------------------------------------             -----------       
  (Address of principal executive offices)                 (zip code)



Registrant's telephone number, including area code      604-299-9321
--------------------------------------------------      ------------



                                       N/A
          -------------------------------------------------------------
          (Former name or former address, if changed since last report)




                                                      Exhibit Index is on page 3
                                                                     Page 1 of 6


<PAGE>   2



ITEM 5. OTHER EVENTS.

Pursuant to Form 8-K, General Instructions F, registrant hereby incorporates by
reference the press release attached hereto as Exhibit 99.


ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

          Exhibit No.  Description
          -----------  -----------
          Exhibit 99   The Loewen Group Inc. Press Release dated May 12, 1999


                                   SIGNATURES

               Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

Dated: May 12, 1999

                                     THE LOEWEN GROUP INC.



                                     By:    /s/ Bradley D. Stam
                                          --------------------------------------
                                     Name:  Bradley D. Stam
                                     Title: Senior Vice President, Law


<PAGE>   3


                                  EXHIBIT INDEX


<TABLE>
<CAPTION>
                                                                         Sequential
Number         Exhibit                                                  Page Number
------         -------                                                  -----------
<S>            <C>                                                      <C>

99             The Loewen Group Inc.                                         4
               Press Release dated May 12, 1999

</TABLE>
§ 520.1855 Ponazuril. ( a ) *Specifications.* Each gram of paste contains 150 milligrams (mg) ponazuril.
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Administer orally 15 mg per kilogram (kg) (6.81 mg per pound (lb)) body weight as the first dose, followed by 5 mg/kg (2.27 mg/lb) body weight once daily for a period of 27 additional days.
( 2 ) *Indications for use.* For the treatment of equine protozoal myeloencephalitis caused by *Sarcocystis neurona.*
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[66 FR 43774, Aug. 21, 2001, as amended at 79 FR 28827, May 20, 2014; 80 FR 34278, June 16, 2015; 80 FR 53459, Sept. 4, 2015; 84 FR 39183, Aug. 9, 2019]